Proactive Investors - Run By Investors For Investors

US giant AbbVie to fund trial of genedrive's hep C test

genedrive thinks its simple out-reach test can help to cure hepatitis C in recovering heroin addicts, people who generally don’t like going to the doctors
hcv id kit
The two-year trial will cover up to 40 pharmacies across three sites in Scotland, Wales and Australia

genedrive PLC (LON:GDR) is to trial its hepatitis C (HCV) testing device in recovering heroin addicts as it looks to see if its diagnostic is cheaper and more effective than what is currently available on the market.

People undergoing treatment for opiate addiction are generally unlikely to travel too far to see a doctor, so genedrive thinks its easy-to-use, outreach kit could be particularly useful in this patient population.

READ: genedrive 'well-placed' after £6mln fundraise

The study will determine if more people with hepatitis C can be treated and cured and will also examine whether Genedrive HCV-ID is a more cost-effective option for the NHS in the UK and Medicare in Australia.

It will be funded by US biopharma giant AbbVie Inc (NYSE:ABBV) and is expected to last for two years and enrol around 140 patients.

“The advancement of molecular diagnostics to the point of need will provide faster treatment decisions to patients who have difficulty accessing traditional centralised services,” said chief executive David Budd.

“We see the requirement for Test and Treat outside of centralised services as a common theme across our menu targets. We are very pleased to be working with Professor Dillon in further proving the cost-effectiveness and clinical benefits of Genedrive HCV-ID in another near patient setting.”

John Dillon, who is leading the study, added: “It is vital that if we are to eliminate HCV, we must find novel ways of using paradigm shifting technology like Genedrive HCV-ID  in care pathways, to bring cure of HCV to the people who need it most.”

View full GDR profile View Profile

Genedrive PLC Timeline

Big Picture
May 23 2019

Related Articles

word cancer under magnifying glass
May 01 2019
The oncology-focused biotech is a mid-clinical-stage therapeutics company.
copd radiograph
April 02 2019
City broker Peel Hunt reckons the recent approvals “support the top-line forecasts in our model that should see Circassia achieve EBITDA positivity in 2020”
February 20 2019
Earlier this month, Tissue Regenix reported full-year results showing revenues more than doubled last year to £11.6mln, up from £5.2mln a year earlier

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use